Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vaccine Therapy + GM-CSF + IL-2 vs Nilutamide in Hormone-Refractory Prostate Cancer
NCT00020254Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Jun 2000
- Primary completion
- Oct 2004
- Modality
- Vaccines & Immunotherapeutics, Viral Vectors, Oncolytic Viruses
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of recombinant vaccinia-prostate-specific antigen vaccine, recombinant vaccinia-B7.1 vaccine and PROSTVAC-F/TRICOM in prostate cancer (PCa) (2 arms), sponsored by National Cancer Institute. Primary endpoint: Time to radiographic evidence of disease progression at 6 months. Started Jun 2000; status: completed.
02
Drugs
recombinant vaccinia-prostate-specific antigen vaccinerecombinant vaccinia-B7.1 vaccinePROSTVAC-F/TRICOM
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00020254.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00020254.